Stockreport

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 [Yahoo! Finance]

Context Therapeutics Inc.  (CNTX) 
PDF Trial marks key milestone in driving pipeline progress “Dosing of the first patient in the CTIM-76 Phase 1 trial represents a key advancement of our clinical pipeline [Read more]